These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25444295)

  • 1. The impact of health economic evaluations in Sweden.
    Heintz E; Arnberg K; Levin LÅ; Liliemark J; Davidson T
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):375-82. PubMed ID: 25444295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.
    Teerawattananon Y; Tritasavit N; Suchonwanich N; Kingkaew P
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):397-404. PubMed ID: 25444298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How health economic evaluation (HEE) contributes to decision-making in public health care: the case of Brazil.
    Elias FT; Araújo DV
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):405-12. PubMed ID: 25444299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?
    Anell A; Persson U
    Eur J Health Econ; 2005 Sep; 6(3):274-9. PubMed ID: 15968561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
    Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International standards for health economic evaluation with a focus on the German approach.
    Riedel R; Repschläger U; Griebenow R; Breitkopf S; Schmidt S; Guhl A
    J Clin Pharm Ther; 2013 Aug; 38(4):277-85. PubMed ID: 23621433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of medical technologies in Sweden.
    Jönsson B
    Soc Sci Med; 1997 Aug; 45(4):597-604. PubMed ID: 9226784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economic evaluation in England.
    Raftery J
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):367-74. PubMed ID: 25444294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aspects of health economic evaluations as a contribution to the priority-setting debate in Germany].
    Brüggenjürgen B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Sep; 53(9):890-5. PubMed ID: 20853085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment in Sweden.
    Carlsson P; Jonsson E; Werkö L; Banta D
    Int J Technol Assess Health Care; 2000; 16(2):560-75. PubMed ID: 10932424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [National and regional prioritisation in Swedish health care: experiences from cardiology].
    Carlsson J
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(6):435-42. PubMed ID: 22857731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
    Drummond M
    J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing accountability for reasonableness--the case of pharmaceutical reimbursement in Sweden.
    Jansson S
    Health Econ Policy Law; 2007 Apr; 2(Pt 2):153-71. PubMed ID: 18634660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of formal benefit/cost evaluations in health system decision making.
    Bloom BS
    Am J Manag Care; 2004 May; 10(5):329-35. PubMed ID: 15152703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.